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Abstract
Formulations of antioxidant enzymes, superoxide dismutase 1 (SOD1, also known as Cu/Zn SOD)
and catalase were prepared by electrostatic coupling of enzymes with cationic block copolymers,
polyethyleneimine-poly(ethylene glycol) or poly(L-lysine)-poly(ethylene glycol), followed by
covalent cross-linking to stabilize nanoparticles. Different cross-linking strategies (using
glutaraldehyde, bis-(sulfosuccinimidyl)suberate sodium salt or 1-Ethyl-3-[3-
dimethylaminopropyl]carbodiimide hydrochloride with N-hydroxysulfosuccinimide) and reaction
conditions (pH and polycation/protein charge ratio) were investigated that allowed immobilizing
active enzymes in cross-linked nanoparticles, termed “nanozymes”. Bi-enzyme nanoparticles,
containing both SOD1 and catalase were also formulated. Formation of complexes was confirmed
using denaturing gel electrophoresis and western blotting and physicochemical characterization
was conducted using dynamic light scattering and atomic force microscopy. In vivo studies
of 125I-labeled SOD1-containing nanozymes in mice demonstrated its increased stability in both
blood and brain and increased accumulation in brain tissues, compared to non-cross-linked
complexes and native SOD1. Future studies will evaluate potential of these formulations for
delivery of antioxidant enzymes to central nervous system to attenuate oxidative stress associated
with neurological diseases.
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Background
Many central nervous system (CNS) diseases (i.e., HIV-associated dementia,1-3 multiple
sclerosis, cerebral palsy, schizophrenia,4 Parkinson's and Alzheimer's diseases,5-7 and
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stroke8,9) have a common inflammatory component, which involves neurodegeneration10
and subsequent microglia activation accompanied by excessive production of reactive
oxygen species (ROS). ROS damage cellular components and further contribute to neuronal
cell death. Efficient transport of antioxidant therapeutics across the blood brain barrier
(BBB) can considerably decrease the amount of ROS in the brain, and subsequently
attenuate neuroinflammation and produce neuroprotection in patients with CNS disorders.11
Two antioxidant enzymes, SOD1 and catalase are known to be very effective scavengers of
ROS. SOD1 catalyzes dismutation of superoxide radical to oxygen and hydrogen
peroxide.12 Catalase catalyzes the decomposition of hydrogen peroxide to water and is one
of the fastest known biocatalysts with highest turnover numbers of all known enzymes
(40,000,000 molecules/second).13 Therefore, these enzymes alone or in combination could
protect neuronal cells from ROS-induced damage and have a potential to improve the
outcome of therapies for CNS disorders.
Synthetic SOD/catalase mimetics, EUK-189 and EUK-207, were shown to provide
neuroprotection under acute ischemic conditions in the rat brain by elimination of free
radicals.14 A few clinical studies evaluated efficacy of α-tocopherol on the rate of
progression of Parkinson's disease.15 However, most studies failed to show significant
improvements in part, perhaps, due to restricted transport of such agents across the BBB.16
Another limitation to the use of these enzymes as therapeutics is their rapid elimination from
circulation and inactivation by proteases present in the body. Attempts to overcome these
difficulties included modification with polyethylene glycol (PEG) (PEGylation)17 or
incorporation into polymeric nanoparticles with PEG corona18-21 that resulted in prolonged
circulation and increased stability of enzymes in the body.22 Unfortunately, encapsulation of
enzymes into nanoparticles often resulted in their inactivation and/or unsatisfactory
loading20,23 and moreover, PEGylation was shown to drastically decrease permeability of
SOD1 across the brain microvessels.24
Here, we develop an alternate approach based on incorporation of these enzymes in polyion
complexes with oppositely charged block copolymers. This approach was previously used
by us and others to immobilize various biopolymers in micelle-like, core-shell particles with
high colloidal stability.25-29 In particular, Kataoka and coworkers formulated positively-
charged lysozyme with negatively-charged poly(ethylene glycol)-poly(α,β-aspartic acid)
block copolymer. Noteworthy, the activity of lysozyme incorporated in such complex was
higher compared to the native enzyme26,27 and it was hypothesized that the elevated
enzymatic activity is a result of substrate concentration in the polyion complexes species26
and/or alterations in binding mode between lysozyme and substrate.27 Incorporation of an
antioxidant enzyme, catalase, into a similar complex with polyethyleneimine-poly(ethylene
glycol) (PEI-PEG) was previously described by us as a strategy for cell-mediated delivery of
catalase to the brain.28
We now report preparation of polyion complexes formed by antioxidant enzymes (SOD1,
catalase) and cationic block copolymers (PEI-PEG or poly(L-lysine)-poly(ethylene glycol)
(pLL10-PEG and pLL50-PEG), followed by covalent cross-linking between polymer and
enzyme. The resulting formulations contain a core of enzyme-polyelectrolyte complex/
conjugate surrounded by a PEG shell (Figure 1). The block copolymer provides protection
for the encapsulated enzyme, which nevertheless remains capable of ROS decomposition
without the need for enzyme release from nanoparticles. In addition, bi-enzyme antioxidant
system comprising of both SOD1 and catalase was encapsulated into the same polyion
complex. Effect of various compositions of enzyme-polyion complexes on physicochemical
characteristics (size, charge, and morphology), enzyme activity, in vitro accumulation and
cytotoxicity, and in vivo behavior (stability and brain delivery) in mice were investigated.
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Based on the results we posit that incorporation of antioxidant enzymes into nanozymes may
improve transport of active enzymes to the brain.
Methods
Materials
Copper/Zinc superoxide dismutase (SOD1) from bovine erythrocytes, Bis-
(sulfosuccinimidyl)suberate sodium salt (BS3), 1-Ethyl-3-[3-
dimethylaminopropyl]carbodiimide Hydrochloride (EDC), N-hydroxysulfosuccinimide (S-
NHS), glutaraldehyde (GA), pyrogallol, sodium dodecylsulfate (SDS), sodium borohydride
(NaBH4), diethylene triamine pentaacetic acid (DTPA), Tris base, phosphate-buffered saline
(PBS), dextran, trichloroacetic acid (TCA), bovine serum albumin (BSA), 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid) (HEPES), Triton X-100 and normal horse
serum were purchased from Sigma-Aldrich (St. Louis, MO). Recombinant human SOD1
was kindly provided by Recsod, Russia. Catalase (bovine liver) was purchased from Sigma
or Calbiochem (San Diego, CA). Polyethyleneimine-poly(ethylene glycol) (PEI2K-PEG10K)
was synthesized as described previously.28 PLL-PEG with two different lengths of pLL (10
and 50 units – 1.6 and 8.2 kDa respectively); pLL10-PEG5K and pLL50-PEG5K were
purchased from Alamanda Polymers Inc. (Madison, AL). The molecular masses and
polydispersity indices (numbers in parentheses) of the copolymers were approximately 12
kDa (1.93), 6.6 kDa (1.13) and 13.2 kDa (1.12) for PEI-PEG, pLL10-PEG and pLL50-PEG,
respectively. Na125I was purchased from PerkinElmer Life (Boston, MA). CATH.a neuronal
cell line (CRL-11179™) was obtained from American Type Culture Collection (Manassas,
VA). Fetal bovine serum (FBS) was purchased from Invitrogen (Carlsbad, CA). CellTiter®
96 aqueous cell proliferation assay was obtained from Promega (Madison, WI). All other
chemicals were obtained from Fisher Scientific unless otherwise noted.
Cell culture
CATH.a cells were cultured in RPMI 1640 medium containing 4 mM L-alanyl-L-glutamine
supplemented with 8% normal horse serum and 4% FBS at 37 °C in 5% CO2 atmosphere.
Preparation of nanozymes
Enzyme-polyelectrolyte complexes were prepared by mixing block copolymers (PEI-PEG or
pLL-PEG) and enzymes (SOD1, catalase or both, as indicated). Briefly, pre-calculated
amounts of the enzyme and the block copolymer were separately dissolved in 50 mM
phosphate buffer, phosphate-buffered saline (PBS), 10 mM HEPES buffer or 10 mM
HEPES-buffered saline (pH 7.4) at room temperature (RT). A solution of the block
copolymer was added drop-by-drop to the enzyme solution and the mixture was gently
vortexed during the entire addition. Complexes were allowed to sit at RT for 30 min before
use in experiments. The charge ratio Z (+/-) was calculated as a ratio of concentration of
amino groups in the block copolymer protonated at pH 7.4 (reported for PEI-PEG30 or as
indicated by supplier for pLL10-PEG and pLL50-PEG) to the concentration of −COOH
groups from glutamic acid and aspartic acid residues in the enzyme (estimated using Protein
Calculator v3.3 software).
To further stabilize these complexes, we explored various cross-linking strategies to
covalently link carboxyl- and/or amino groups of the enzyme to the amino groups of
polycations. Cross-linking of pre-formed complexes was carried out using GA/NaBH4, BS3
or EDC/S-NHS. A list of nanozymes is presented in Table 1.
In case of GA/NaBH4 and BS3, cross-linker excess was defined as the molar ratio of GA or
BS3 to the total number of amino groups of polymer and enzyme (0.5-5 mM NaBH4 was
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added for 15-60 min after overnight incubation of the reaction mixture containing 2 to 100-
fold GA excess). In case of EDC/S-NHS, it was defined as the molar ratio of EDC to the
total number of carboxylic groups of the enzyme (5-10 mM S-NHS was added 5 min after
EDC addition). Cross-linker excesses were varied from 2 to 100-fold as indicated. All mono
enzyme samples were prepared in PBS, pH 7.4. In case of “bi-enzyme” samples, pH of the
reaction buffer was varied from 5.2 to 7.4. Reaction mixtures were incubated overnight at 4
°C, and unreacted reagents were removed by desalting using NAP™-10 columns (GE
Healthcare Bio-Sciences Corp. Piscataway, NJ). Wherever indicated, samples were filtered
using a 20 nm (SOD1 nanozymes) or 100 nm (catalase nanozymes) pore size filter prior to
use in experiments.
Electrophoretic Retention
The cross-linking of enzyme-polyion complexes was confirmed by polyacrylamide gel shift
assay. Samples were loaded on a 10% polyacrylamide gel under denaturing conditions.
Protein bands were visualized with sheep polyclonal anti-SOD (Calbiochem, San Diego,
CA) for SOD1, and rabbit polyclonal anti-catalase (Ab 1877, Abcam Inc, Cambridge, MA)
for catalase, and secondary horseradish peroxidase anti-rabbit Ig antibody (Amersham Life
Sciences, Cleveland, OH).
Enzyme Activity
Enzyme activity in samples was measured using pyrogallol autoxidation followed by
superoxide radical dismutation (for SOD1) and hydrogen peroxide decomposition (for
catalase) methods, respectively (See SUPPLEMENTARY SECTION for complete details).
Dynamic Light Scattering (DLS)
Effective hydrodynamic diameter and zeta-potential (ζ-potential) of nanozymes was
measured by photon correlation spectroscopy using Zetasizer Nano ZS (Malvern
Instruments Ltd, UK) in a thermostatic cell at a scattering angle of 173° using previously
described methods.31,32
Atomic Force Microscopy (AFM)
Five μL of an aqueous dispersion (ca. 0.01 mg/mL) was deposited onto positively-charged
aminopropylytriethoxy silane (APS) mica surface33-35 for 2 min, washed with water and
dried under argon atmosphere. AFM imaging was performed using a Multimode NanoScope
IV system (Veeco, Santa Barbara, CA) operated in tapping mode. Particle widths and
heights were estimated using Femtoscan software (Advanced Technologies Center, Russia).
Preparation of 125I-labeled SOD1
SOD1 was labeled with Na125I using IodoBEADS Iodination reagent (Pierce
Biotechnology, Rockford, IL). Briefly, Na125I (500 μCi) was pre-incubated with
IodoBEADS for 5 min, and then added to pre-calculated amount of SOD1 solution. The
reaction mixture was incubated at RT for 15 min and purified on a NAP™-10 column. 125I-
labeled-SOD1 nanozymes were prepared as described earlier.
Cellular Accumulation
Accumulation of various nanozymes in bovine brain microvessel endothelial cells
(BBMEC) was evaluated as described earlier.36 Briefly, confluent cell monolayers grown on
24-well plates were pre-treated with assay buffer for 30 min at 37 °C and then incubated
with 125I-labeled nanozymes for 1 h. Cells were then washed with ice-cold PBS, and
solubilized in 1% Triton X-100 for subsequent determination of radioactivity counts (counts
per minute; CPM) in a gamma counter. The cellular accumulation was normalized to
Klyachko et al. Page 4













cellular protein content determined by Pierce® BCA Protein Assay. Results are reported as
average ± standard error mean (SEM) of quadruplicate samples.
Cytotoxicity Evaluation
Cytotoxicity of selected nanozymes was determined using the CellTiter® 96 Aqueous Cell
Proliferation Assay (MTS). Twenty-thousand cells seeded in a 96-well plate 24 h before the
experiment was incubated with increasing concentration of the respective samples in 100 μL
of complete culture medium. The medium was removed after 24 h and replaced with a
mixture of 100 μL of fresh RPMI and 20 μL of MTS reagent solution. The cells were
incubated for 1 h at 37 °C in a CO2 incubator. The absorbance of each sample was then
measured at 490 nm to determine cell viability. The results are expressed as the mean
percentage cell viability relative to untreated cells ± SEM.
Animals
Male Balb/c mice (Charles River Laboratories, USA) 6-8 weeks old were used in the study.
All procedures were approved by the Institutional Animal Care and Use Committee of the
University of Nebraska Medical Center. Animals were housed and humanely handled in
accordance with the Principles of Animal Care outlined by National Institutes of Health.
In Vivo Studies
Male Balb/c mice (8 weeks old) were anesthetized with a cocktail of ketamine (80 mg/kg)
and xylazine (5 mg/kg) administered intraperitonially. Mice were injected with either
native 125I-SOD1, non-cross-linked 125I-SOD1/pLL10-PEG nanozyme or cross-linked 125I-
SOD1/pLL10-PEG. The nanozymes were prepared at Z = 10 and the cross-linked using 5-
fold EDC excess (S-NHS: 5 mM) as described above. Nanozymes in saline were
administered intravenously (i.v.) via tail vein in a 100 μL volume (1 mg SOD1/mL). One
hour after injection, the abdomen and rib cage were opened and blood was collected from
the heart. Twenty mL of lactated ringer's solution (LR) (B Braun Medical Inc., Irvine, CA)
was then perfused through the left ventricle of the heart. Whole brains were dissected and
weighed and the levels of radioactivity were counted in a gamma counter.
TCA Precipitation
Acid precipitation method was used to estimate stability of SOD1 by following 125I label
degradation.37 Brain and serum samples were placed in an ice-cold glass homogenizer. The
brain was homogenized by 10 vertical strokes in 1% w/v BSA acidified LR (pH 4.0).
Homogenates were centrifuged at 4000 ×g for 25 min at 4 °C. The resulting supernatant
(soluble fraction) and blood serum samples were precipitated with 30% v/v of TCA and
centrifuged at 4000×g for 35 min. Radioactive counts (CPM) of resulting supernatant and
precipitate (pellet) correspond to free 125I label and enzyme-bound 125I, respectively.
Stability of nanozymes was assessed as a ratio of enzyme-bound 125I (pellet CPM) to
overall 125I radioactivity (supernatant CPM + pellet CPM). The results obtained in these
experiments represent average quantities of SOD1 in each sample/fraction without
discrimination of its interstitial or intercellular localization in the organs.
Capillary Depletion
Male Balb/c mice were anesthetized as described earlier. Animals were treated and brain
and serum samples were collected. The brain was homogenized by 10 vertical strokes in 0.8
mL of physiological buffer (10 mM HEPES, 141 mM NaCl, 4 mM KCl, 2.8 mM CaCl2, 1
mM MgSO4, 1 mM NaH2PO4, and 10 mM D-Glucose; pH 7.4). Dextran solution (1.6 mL of
a 26% solution) was added to the homogenate, mixed, and homogenized with 3 additional
vertical strokes. The homogenate was centrifuged at 4000×g for 25 min at 4 °C. The
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resulting supernatant (brain parenchymal fraction) and pellet (capillary fraction) were
separated. The levels of radioactivity in the capillary and brain parenchymal fractions were
counted in a gamma counter. The results are expressed as a compartment (parenchyma or
capillaries)/serum ratio. Initial radioactivity values obtained in this experiment correspond to
overall accumulation of complexes in the brain compartment that includes both 125I-labeled
complexes as well as free label that dissociated from the nanoparticles. In order to quantify
the presence of intact complexes that retain their structure in the brain compartments, initial
radioactivity values obtained in capillary depletion experiment were multiplied by a ratio of
enzyme-bound 125I (pellet CPM) to overall 125I radioactivity (supernatant CPM + pellet
CPM) obtained in the acid precipitation experiment.
Statistical Analysis
All data are presented as the average ± SEM (n=4 or 5). Tests for significant differences
between the groups were done using one-way ANOVA with multiple comparisons (Kruskal-
Wallis) using GraphPad Prism 4.0 (GraphPad software, San Diego, CA). A minimum p
value of 0.05 was set as the significance level in all cases.
Results
Preparation of cross-linked nanozymes
The polyion complexes were prepared by simple mixing of aqueous solutions of
corresponding enzymes (SOD1 or catalase, or both) and block copolymers (PEI-PEG or
pLL-PEG). Both SOD1 and catalase are negatively charged under physiological conditions
(pI values are 4.95 and 5.8 for SOD1 and catalase, respectively). Unless stated otherwise,
polyion complexes were prepared at pH 7.4 that favored electrostatic coupling of the
enzyme and the block copolymers. Cross-linking of polyion complexes using GA/NaBH4,
BS3, or EDC/S-NHS were done as described earlier.
Electrophoretic retention—The formation of cross-linked polyion complexes was
confirmed by denaturing gel electrophoresis. Both enzymes are oligomeric proteins and
dissociated under denaturing conditions into individual subunits of 16 kDa (SOD1) and 60
kDa (catalase) (Figure 2).
The migration pattern was different in case of cross-linked complexes. Usually, there was
disappearance or retardation of the protein band, presumably due to inability of cross-linked
complexes to migrate through the gel (lanes S3, S4, S7, C2 and SC3). Few conjugates did
migrate through the gel, but their estimated molecular masses were greater than those of the
respective oligomeric subunits (lanes S2, C3, C4, C9, SC4, SC7, SC6 and SC8). Complete
disappearance of free subunits, suggesting nearly 100% conjugation was observed when
PEI-PEG and BS3 (7 to 10-fold excess over NH2-groups) were used with both enzymes
(lanes S3, C3, SC3, SC6) or pLL10-PEG and EDC/S-NHS (20 to 25-fold excess over
−COOH groups) was used with catalase (lane C9). In contrast, use of GA/NaBH4 (2 to 5-
fold excess over NH2 groups) and EDC/S-NHS (as earlier) resulted in partial conjugation
under the experimental conditions (lanes S2, S4, S7, C2, C4, SC4, SC7 and SC8). In some
cases, the extent of cross-linking could be improved by increasing the amount of the cross-
linkers. For example, at 100-fold excess of GA the conjugation was nearly complete (not
shown), however, the loss of enzyme activity (ca. 50%) prompted us to use lower excesses
of GA (about 2 to 7-fold).
In order to obtain two enzymes in the same nanoparticle, we tried to enhance interactions of
these enzymes with each other by rendering them oppositely charged using low pH of ∼5.2,
which lies between pI values of 4.95 (SOD1) and 5.8 (catalase). However, this decreased the
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efficiency of cross-linking and led to a considerable loss of catalase activity. Therefore, in
most cases, we carried out the cross-linking at relatively high pH ≥ 6.8 where both enzymes
were negatively-charged. Formation of SOD1-catalase bi-enzyme nanoparticles was
confirmed by visualizing both proteins within the bands of the same molecular mass using
anti-SOD1 and anti-catalase antibodies (lanes SC4, SC7, SC6 and SC8). However, in few
cases these antibodies stained bands of different molecular masses, suggesting that the
enzymes segregated into particles of different type (lanes SC2 and SC3).
Characterization of nanozymes
Enzyme activity—Catalytic activity of SOD1 and catalase in nanozymes was measured as
described earlier. Linear dependence of SOD1 and catalase catalytic activities on enzyme
concentrations (Figure S1) was observed in the concentration range used; this allowed us to
analyze changes in the activity of formulated enzymes using reaction rates that were
normalized to the respective enzyme concentrations. As a quantitative analysis of catalase
activity, the dependence of the reaction rate on substrate concentration was studied and
kinetic parameters, maximal reaction rate (kinetic constant; kcat) and apparent Michaelis
constant (Km) were obtained using double reciprocal coordinates (Figure S2). Apparent
kinetic parameters (kcat and Km: 6.5×105 s-1 and 63 mM, respectively) calculated for
catalase were found to be similar to those reported in published literature.38 For SOD1, the
direct measurement of the superoxide dismutation is not possible. Therefore, enzyme
activity was assayed indirectly by autoxidation of pyrogallol and was expressed as the
amount of enzyme that resulted in 50% inhibition in rate of autoxidation. Two different
substrate systems were also used for quantitative analysis of SOD1 activity, riboflavin/Nitro
Blue Tetrazolium (Figure S3A) and luminol/xanthine/xanthine oxidase/oxygen systems
(Figure S3B).
Before cross-linking, both enzymes retained 100% activity in the polyion complexes (Table
2). Significantly high levels of activity (at least 70%) were retained after cross-linking in
most cases. Interestingly, the chemical structure of the block copolymer did not affect the
activity after cross-linking. However, the type of cross-linker and reaction conditions
showed a significant effect. For example, enzymes cross-linked with GA/NaBH4 retained
70-100% of activity (Table 2 and Figures S1B and S2) strongly depending not only on GA
excess but also reduction time with NaBH4 (lesser time correlated with lower activity loss).
In contrast, conjugation of nanozymes with EDC/S-NHS resulted in mild activation of the
enzyme (residual activity 105-115%). Furthermore, as already mentioned low pH ∼5.2
resulted in irreversible inactivation of both enzymes (not shown).
Particle size—Hydrodynamic size (size) and surface charge (ζ-potential) of the
nanozymes that showed considerable retention of enzyme activity was determined using
DLS (Table 3A). Particles of native SOD1 showed a small size (4.6 nm), which was close to
the theoretical diameter (4.5 nm) of a single protein globule estimated from molecular mass
of the enzyme (32 kDa). In contrast, DLS analysis of native catalase revealed bimodal size
distribution with a smaller size of 10 nm corresponding to a single globule and a larger size
of 63 nm, which most likely represented aggregates. All complexes (cross-linked or non-
cross-linked) were nearly electroneutral or weakly-charged. Compared to the native enzyme
molecules, both SOD1- and catalase-based complexes displayed an increase in size and in
most cases, their distribution was bimodal. In selected cases, we demonstrated that the
particle uniformity can be improved by filtering nanozymes through a 20/100 nm pore size
filter. This procedure resulted in SOD1 and catalase complexes of unimodal size distribution
(Table 3B). It should be noted that there was no loss of enzyme activity (normalized to
protein concentration) upon filtering.
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Particle morphology—Morphology and number-average sizes of nanozymes were
studied by AFM. Typical image of cross-linked complexes is shown in Figure 3A. Analysis
of the images revealed that the nanozymes displayed a broad range of sizes and appeared to
be spherical particles.
Their number-average diameters are presented in Table S1. For example, complexes that
contained small particles having diameters ca. 25 nm also had bigger particles with
diameters ca. 45-100 nm. These observations were in good agreement with the DLS data
showing bimodal distribution. Native SOD1 showed smaller particles compared to SOD1
complexes, while native catalase showed aggregates in addition to small globular particles.
It is worth mentioning that imaging in air usually provides lower numbers for the height as a
result of the drying process, but higher numbers for the width, due to the tip convolution
effect. In addition, interactions between the particles and positively charged mica might also
affect size measured by AFM. AFM image of filtered cross-linked particles is shown in
Figure 3B, demonstrating particles of spherical morphology and narrower distribution, in
agreement with DLS data (Table 3B).
Accumulation of cross-linked nanozymes in BBMEC monolayers
Here, we used BBMEC monolayers as an in vitro model of BBB to evaluate cellular uptake
of cross-linked nanozymes. We selected EDC/S-NHS as the cross-linking approach since
the resulting nanozymes showed little if any loss in enzyme activity (Table 2). The
following cross-linked nanozymes were prepared using pLL-PEG and EDC/S-NHS – cl
SOD1/pLL10-PEG (Z=1), cl SOD1/pLL10-PEG (Z=10) and cl SOD1/pLL50-PEG (Z=1).
BBMECs were incubated with 125I-labeled SOD1 nanozymes and accumulation was
determined in cell lysates (Figure 4). Significant increase in cellular uptake was observed in
case of nanozymes prepared using pLL10-PEG and pLL50-PEG block copolymers at Z=1.
Interestingly, when a higher excess of the block copolymer was used (pLL10-PEG, Z=10)
the uptake levels were not statistically different (P>0.05) from that of native SOD1, which
may be due to a toxic effect of the excess polycation.
Cytotoxicity of nanozymes in CATH.a neurons
Here, CATH.a neurons were used as an in vitro model to evaluate cytotoxicity of the
following samples – native SOD1, non-cross-linked and EDC/S-NHS cross-linked SOD1/
pLL10-PEG (Z=10) nanozymes (Figure 5). SOD1 concentration in each group ranged from 1
to 200 μg/mL (it should be noted that the SOD1 concentration used in following in vivo
experiments is 50 μg/mL: 100 μg/mouse; assuming a blood volume of 2 mL). Almost no
decrease in cell viability was observed in case of native SOD1 with an exception at 50 μg/
mL concentration, but the viability was again >100% at higher concentrations. Cells treated
with cross-linked nanozymes either showed the same/slightly higher viability (lower
cytotoxicity) compared to those treated with non-cross-linked nanozymes; especially at
concentrations ≥ 25 μg/mL. IC50 value could not be determined since the cell viability at the
highest concentration used (200 μg/mL) was still ∼70-72%.
In vivo stability of SOD1 nanozymes
Further, we examined the stability of SOD1 in cross-linked and non-cross-linked nanozymes
after i.v. administration in mice. The protein stability was determined using TCA
precipitation in brain homogenates and blood serum 1 h after injection (Figure 6). At this
time point, nearly 80% of native SOD1 in the brain and over 50% SOD1 in the serum were
degraded. Interestingly, the non-cross-linked nanozyme did not show any improvement
compared to native SOD1 despite the presence of a 10-fold excess of polycation in the
formulation. However, once it was cross-linked, the stability of SOD1 was significantly
increased both in the brain and blood. In this case, the amount of non-degraded protein was
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increased compared to native SOD1 or non-cross-linked nanozyme by ca. 1.8 and 1.2-fold in
the brain and blood, respectively.
Brain delivery of cross-linked nanozymes
Ability of nanozymes to deliver SOD1 to the brain was studied in a capillary depletion
experiment (Figure 7). As earlier, samples were processed using acid precipitation technique
to confirm that the radioactivity readout corresponded to enzyme-bound 125I. A 1.7- and 10-
fold increase in compartment (parenchyma and capillaries, respectively) to serum ratios
were observed in case of cross-linked nanozymes, compared to native SOD1 and non-cross-
linked nanozymes. As earlier, we noted no significant differences between delivery of native
SOD1 and non-cross-linked nanozymes.
Discussion
SOD1 and catalase are negatively-charged at physiological conditions. Physical mixing of
enzymes with positively-charged block copolymers resulted in spontaneous formation of
polyion complex nanoparticles, known as “block ionomer complex”39 with enzyme/
polycation complex core and PEG shell. The reaction proceeded rapidly (minutes) at pH 7.4
due to the electrostatic coupling of negatively-charged carboxylic groups of enzymes and
positively-charged amino groups of PEI or pLL in the block copolymers. Notably, both
SOD1 and catalase retained nearly 100% of the initial catalytic activity after complexation.
Compared to the DNA-based complexes studied earlier, nanozymes are less stable because
of lower density of negative charges in the protein globule vs. DNA.40 Therefore, they can
dissociate upon strong dilution or react with negatively charged competitor molecules, such
as serum proteins, leading to premature release of the enzyme. To further stabilize these
complexes in circulation, we explored various cross-linking strategies to covalently link
carboxyl- and/or amino groups of the protein to the amino groups of polycations. We used
water-soluble cross-linking reagents: 1) EDC/S-NHS; 2) GA/NaBH4; and 3) BS3.
We demonstrated that use of all three linkers resulted in cross-linked nanoparticles.
Interestingly, use of BS3 resulted in uniform particles, which were larger compared to other
nanozymes. We estimated that such particles may contain at least few thousands of SOD1
molecules. In contrast, GA and EDC/S-NHS resulted in formation of heterogeneous particle
population. In most cases we obtained nanozymes with bimodal size distribution. The
heterogeneity of nanozymes was also supported by AFM and gel electrophoresis data.
Hydrodynamic size of particles can dramatically affect their in vivo behavior by influencing
parameters such as blood half-life, hepatic filtration, renal clearance, and
biodistribution.41-43 Aggregated particles were removed by filtration without any
considerable loss in enzyme activity (normalized to protein content) and resulting
nanozymes were of unimodal size distribution. Interestingly, with few exceptions, the sizes
of the resulting nanoparticles and their charge did not depend on the chemical structure of
the block copolymers, composition of the polyion complexes or cross-linker used. In all
cases the ζ-potentials of the nanoparticles were either electroneutral, weakly-positive or
weakly-negative. Altogether, our data were consistent with formation of stoichiometric
polyion complexes that were almost electroneutral. They correspond to either complexes of
single and/or several protein molecules as presented in Figure 1. Notably, even when a
significant excess of block copolymer (pLL10-PEG, Z=10) was used the ζ-potential
remained low, albeit weakly-positive and somewhat greater than the ζ-potential of
stoichiometric complexes (Z=1). This suggests that excess of the polycation beyond
stoichiometry cannot be incorporated in the block ionomer complex. In fact, a similar
behavior is known for the block ionomer complexes formed between polynucleotides and
cationic block copolymers. Such complexes are nearly electroneutral in contrast to polyion
complexes formed by polynucleotides and homopolymer polycations that can incorporate
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excess of polycation and show an increase in positive charge at higher Z values. It appears
that incorporation of excess of cationic block copolymers in block ionomer complexes is
hindered by steric repulsion of the non-ionic PEG chains linked to the polycation
molecules.44
The chemical structure of block copolymer in polyion complex affected neither size nor
enzyme activity of the nanozymes. The most profound effect on activity was observed when
different cross-linkers were used. We speculate that reactivity of the linker might play an
important role in this effect. For instance, GA is known to be the most reactive agent45
among the cross-linkers used and therefore it might affect amino acids in proximity to the
active site of the enzyme. Furthermore, high reactivity of GA leads to multiple byproducts45
that might affect activity of the enzyme. In addition, conjugation with GA requires the
second step of Shiff-base reduction with NaBH4, which can contribute to enzyme
inactivation (especially in the case of a heme-containing protein, catalase).
Although the idea to incorporate SOD1 and catalase in one particle might appear attractive
from the standpoint of therapeutic applications, the technical difficulties of combining these
two proteins together are significant. In particular, we observed segregation of two enzymes
into different particles in some cases (Figure 2). An attempt to overcome this by increasing
electrostatic interactions between SOD1 and catalase at low pH was offset by loss of
enzyme activity and decreased cross-linking efficacy.
We further demonstrated that incorporation of SOD1 in nanozymes can increase its uptake
in BBMEC monolayers, which were used as an in vitro model of BBB. Future studies will
determine pathways of transport of these nanozymes in cells. We further tested cytotoxicity
of selected formulations and demonstrated that CATH.a neurons treated with non-cross-
linked or cross-linked nanozymes showed cell viabilities >70% even at the highest
concentration tested, suggesting the promise of developing such systems for CNS delivery.
Significant increase in the amount of 125I-SOD1 observed in case of cross-linked nanozymes
in the acid precipitation study most-likely resulted from its improved stability against
polyelectrolyte exchange reactions with serum proteins. However, we noted no
improvement in stability of non-cross-linked nanozymes compared with native SOD1. Non-
cross-linked nanozymes most-likely dissociated upon interactions with serum proteins and
thus its behavior was similar to that of the native enzyme. Ongoing efforts in our lab
demonstrate that fractionation using size exclusion chromatography under conditions that
disassemble the non-cross-linked particles (mobile phase contained 0.15 M NaCl) result in a
homogenous population exclusively comprised of cross-linked particles (manuscript in
preparation). We believe that use of homogenous particles will further improve stability in
vivo. Results from the capillary depletion study demonstrated increased delivery of 125I-
SOD1 to both brain parenchyma and capillaries, suggesting that cross-linking improved
metabolic stability of SOD1 across the BBB. Non-cross-linked particles behaved similar to
native SOD1 most likely due to their dissociation as discussed above.
In summary, we prepared nanosized polyelectrolyte complexes of antioxidant enzymes by
self-assembly of SOD1 or catalase with oppositely-charged block ionomers. Different
synthetic strategies that allowed immobilizing active enzymes in cross-linked nanoparticles
were evaluated. Preliminary evidence of utility of such nanozymes for the delivery of
antioxidant enzymes in vivo was demonstrated. Overall, this study may lead to the
development of a new technology for the delivery of antioxidant enzymes to CNS in order to
attenuate pathology-associated oxidative stress.
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Figure 1. Schematic representation of polyion complexes
Complexes spontaneously form in aqueous solution as a result of electrostatic coupling of
the enzyme and cationic block copolymer. Although only one protein globule is
schematically shown here, the polyion complex may contain several protein globules. Cross-
linker was added to pre-formed complexes that resulted in covalent stabilization.
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Figure 2. Gel retardation assay of enzyme/polyion complexes
Five μg protein was loaded on a 10% polyacrylamide gel and electrophoresis was carried out
as described earlier. Bands were visualized with A) anti-SOD1 and B) anti-catalase
polyclonal antibodies. L refers to ladder. nS and nC refer to native SOD1 and catalase,
respectively. The lanes correspond to the following samples of cross-linked nanozymes
listed in Table 1: S2, S3 and S4 – SOD1/PEI-PEG (Z=1) cross-linked using GA, BS3 and
EDC/S-NHS respectively; S7 – SOD1/pLL10-PEG (Z=10) cross-linked using EDC/S-NHS;
C2, C3 and C4 - catalase/PEI-PEG (Z=1) cross-linked using GA, BS3 and EDC/S-NHS,
respectively; SC2, SC3, SC4 – SOD1-catalase/PEI-PEG (Z=1) cross-linked using GA, BS3
and EDC/S-NHS, respectively; SC6, SC7, SC8 (all prepared at Z=1) indicate SOD1-
catalase/pLL10-PEG (BS3), SOD1-catalase/pLL10-PEG (EDC/S-NHS) and SOD1-catalase/
pLL50-PEG (EDC/S-NHS) respectively.
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Figure 3. AFM image of SOD1/pLL50-PEG complexes cross-linked using EDC/S-NHS
(A) not-filtered (B) filtered. Samples were prepared on an APS mica substrate, dried under
argon and images were acquired on a Multimode NanoScope IV system. Scan size: 2 × 2
μm.
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Figure 4. Accumulation of cross-linked SOD1 nanozymes and native SOD1 in BBMEC
monolayers
Cells were incubated with 125I-SOD1 formulations or native SOD1 for 1 hour, washed,
lysed and 125I activity was measured in a gamma counter. SOD1 concentration in the
incubation media was 1 mg/mL. The amount of cell-associated 125I was normalized to
cellular protein content and values reported are mean ± SEM (n = 4).
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Figure 5. Cytotoxicity of non-cross-linked and cross-linked nanozymes in CATH.a neurons
Cells were incubated for 24 h with either native SOD1, non-cross-linked SOD1/pLL10-PEG
(Z=10), and SOD1/pLL10-PEG (Z=10) cross-linked using EDC/S-NHS in concentrations
ranging from 1 to 200 μg/mL (SOD1). Cell viability was measured using a commercially
available MTS assay kit and results are expressed as mean ± SEM (n = 3).
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In vivo stability of SOD1 in nanozyme formulations. The % 125I-SOD1 is the fraction
of 125I precipitated by TCA in brain homogenates or serum. Samples include native SOD1,
non-cross-linked SOD1/pLL10-PEG (Z=10), and SOD1/pLL10-PEG (Z=10) cross-linked
using EDC/S-NHS. Hundred μL of sample (1 mg SOD1/mL) was injected i.v. into mice;
blood and brain tissue were collected 1 hour post-injection and processed as described
earlier. Values are mean ± SEM (n=4 or 5). Statistical comparisons were performed by
Kruskal-Wallis ANOVA (*P<0.05).
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Figure 7. Brain delivery of SOD1 formulations
Hundred μg of each sample was injected i.v. into mice; brain tissues were collected 1 h post-
injection, homogenized and fractionated in a dextran gradient. Values reported indicate
average ± SEM (n=4 or 5) and statistical comparisons were performed by Kruskal-Wallis
ANOVA (*P<0.05; **P<0.001).
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Table 1
Description of nanozymes
Sample ID Sample Block copolymer Z Cross-linker
nS SOD1 (native enzyme) - - -
S1 non-cl* PEI-PEG 1 -
S2 cl† PEI-PEG 1 GA
S3 cl PEI-PEG 1 BS3
S4 cl PEI-PEG 1 EDC/S-NHS
S5 cl pLL50-PEG 1 EDC/S-NHS
S6 non-cl pLL10-PEG 10 EDC/S-NHS
S7 cl pLL10-PEG 1 EDC/S-NHS
S8 cl pLL10-PEG 10 EDC/S-NHS
nC catalase (native enzyme) none - -
C1 non-cl PEI-PEG 1 -
C2 cl PEI-PEG 1 GA
C3 cl PEI-PEG 1 BS3
C4 cl PEI-PEG 1 EDC/S-NHS
C5 cl pLL50-PEG 1 EDC/S-NHS
C6 cl pLL50-PEG 2 EDC/S-NHS
C7 cl pLL50-PEG 5 EDC/S-NHS
C8 non-cl pLL10-PEG 1 -
C9 cl pLL10-PEG 1 EDC/S-NHS
SC1 SOD1-catalase; non-cl PEI-PEG 1 -
SC2 SOD1-catalase; cl PEI-PEG 1 GA
SC3 SOD1-catalase; cl PEI-PEG 1 BS3
SC4 SOD1-catalase; cl PEI-PEG 1 EDC/S-NHS
SC5 SOD1-catalase; non-cl pLL10-PEG 1 -
SC6 SOD1-catalase; cl pLL10-PEG 1 BS3
SC7 SOD1-catalase; cl pLL10-PEG 1 EDC/S-NHS
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Table 2
Residual enzyme activity of nanozymes
Sample SOD1 residual activity, %* Catalase residual activity, %* pH Cross-linker
SOD1 100 - 7.4 -
SOD1 100 - 6.8 -
SOD1/PEI-PEG; non-cl† 100 - 7.4 -
SOD1/PEI-PEG; cl‡ 88 - 7.4 GA/NaBH4
SOD1/PEI-PEG; cl 91 - 7.4 BS3
SOD1/PEI-PEG; cl 115 - 7.4 EDC/S-NHS
SOD1/pLL10-PEG; cl 115 - 7.4 EDC/S-NHS
SOD1/pLL50-PEG; cl 109 - 7.4 EDC/S-NHS
catalase (cat) - 100 7.4 -
cat - 60 6.8 -
cat/PEI-PEG; non-cl - 100 7.4 -
cat/pLL10-PEG; non-cl - 100 7.4 -
cat/PEI-PEG; cl - 80 7.4 GA/NaBH4
cat/PEI-PEG; cl - 100 7.4 BS3
cat/PEI-PEG; cl - 95 7.4 EDC/S-NHS
cat/pLL10-PEG; cl - 100 7.4 EDC/S-NHS
SOD1-cat/PEI-PEG; non-cl 100 100 6.8 -
SOD1-cat/pLL10-PEG; non-cl 100 100 6.8 -
SOD1-cat/PEI-PEG; cl 80 71 6.8 GA/NaBH4
SOD1-cat/pLL10-PEG; cl 95 78 6.8 GA/NaBH4
SOD1-cat/pLL10-PEG; cl 85 88 7.4 GA/NaBH4
SOD1-cat/pLL10-PEG; cl 70 98 6.8 BS3
SOD1-cat/PEI-PEG; cl 100 105 6.8 EDC/S-NHS
SOD1-cat/pLL10-PEG; cl 97 82 6.8 EDC/S-NHS
SOD1-cat/pLL10-PEG; cl 110 115 6.8 EDC/S-NHS
*
Residual enzymatic activity of nanozymes (A/A0) was calculated based on native enzyme activity (A0) at the same pH. The initial activity values





Cross-linker excesses were 7 fold for GA and BS3 (over NH2 groups in enzyme and polymer), and 24-fold for EDC/S-NHS (over -COOH groups
in enzyme).
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Table 3
Physicochemical properties of selected nanozymes measured using DLS
Effective diameter, nm
Sample Linker ζ-potential, mV
Peak 1 Peak 2
SOD1 - 4.6 - -2.6
SOD1/PEI-PEG; non-cl* - 6.1 74.5 -1.5
SOD1/PEI-PEG; cl† BS3 - 97.4 0.3
SOD1/PEI-PEG; cl EDC/S-NHS 6.2 63.6 -1.3
SOD1/pLL10-PEG; cl EDC/S-NHS 6.3 64.2 -2.4
SOD1/pLL10-PEG‡; cl EDC/S-NHS 5.5 72.0 1.3
SOD1/pLL50-PEG; cl EDC/S-NHS 5.8 81.0 2.6
catalase (cat) - 10.0 63 -5.0
cat/PEI-PEG; non-cl - 12.5 68.4 0.5
cat/PEI-PEG; cl GA 40.8 644.3 n.d.§
cat/PEI-PEG; cl BS3 10.6 59.5 -1.2
cat/PEI-PEG; cl EDC/S-NHS 10.6 52.7 -0.3
cat/pLL10-PEG; non-cl - 12.0 71.0 -2.4
cat/pLL10-PEG; cl EDC/S-NHS 12.0 28.2; 504 n.d.§
SOD1-cat/PEI-PE; cl GA - 30.0 n.d.§
SOD1-cat/PEI-PEG; cl BS3 - 91.9 -2.7
SOD1-cat/PEI-PEG; cl EDC/S-NHS 11.7 91.0 -2.9
SOD1-cat/pLL10-PEG; cl EDC/S-NHS 14.0 135.4 -1.3
All nanozymes were prepared at Z=1 (unless indicated otherwise).
*non-cross-linked, †cross-linked, ‡Z=10; §not determined
Measurement error was typically ≤ 5% of reported values.
Table 3B Diameter of filtered nanozymes measured using DLS
Sample* Linker Dz, nm† PdI‡ ζ, mV§
SOD1 - 5.2 ± 0.1¶ 0.1± 0.03 -2.3 ± 0.5
SOD1/pLL50-PEG; non-cl# - 11.2 ± 0.5 0.2 ± 0.02 6.2 ± 0.5
SOD1/pLL50-PEG; cl** EDC/S-NHS 9.7 ± 0.1 0.1 ± 0.02 0.6 ± 0.1
catalase (cat) - 11.5 ± 0.1¶ 0.2± 0.01 n.d††
cat/pLL50-PEG; non-cl - 16.1 ± 0.1 0.2 ± 0.01 n.d.
cat/pLL50-PEG; cl EDC/S-NHS 19.8 ± 0.3 0.2 ± 0.01 n.d.
SOD1 and catalase formulations were prepared in 10 mM HEPES and 10 mM HEPES-buffered saline (pH 7.4), respectively.
*




polydispersity index (PDI) and
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§
ζ-potential. Data are mean ± SD of triplicate measurements.
¶






ζ-potential not determined because of high ionic strength.
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